Mendra, a biopharmaceutical company headquartered in San Francisco, USA, recently announced its official establishment and the concurrent completion of an oversubscribed $82 million Series A funding round. This round was jointly led by OrbiMed, 8VC, and 5AM Ventures, with participation from institutions such as Lux Capital and Wing VC. The funds will be used to advance the rare disease treatment research and development pipeline and to build global commercialization capabilities.
Mendra focuses on the rare disease treatment field, committed to optimizing therapy R&D processes and improving drug accessibility through innovative technology platforms. The company plans to use this funding to accelerate preclinical research on core projects while establishing a commercialization team covering major global markets. Its R&D strategy emphasizes interdisciplinary collaboration, integrating cutting-edge technologies such as gene editing and artificial intelligence to shorten the cycle from lab to patient for rare disease treatments.
"There remains a significant unmet medical need in the current rare disease treatment landscape," said Mendra's CEO. "Our mission is to break down traditional R&D barriers and enable more patients to access effective treatments in a timely manner."
